Global Cancer Immunotherapy Drugs 麻豆原创 Growth (Status and Outlook) 2024-2030

Publication ID:

LPI07242117

Publication Date:

July 8, 2024

Pages:

128

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Immunotherapy is a type of medical treatment that harnesses the body's own immune system to fight diseases, particularly cancer. Unlike traditional treatments such as chemotherapy and radiation therapy, which directly target cancer cells, immunotherapy stimulates the body's natural defenses to identify and destroy cancer cells more effectively. It is a type of personalized treatment. (Immunotherapy is often tailored to the patient's specific cancer and immune system. Biomarker testing is sometimes performed to determine the suitability of certain immunotherapy drugs.)
The global Cancer Immunotherapy Drugs market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
The 鈥淐ancer Immunotherapy Drugs Industry Forecast鈥� looks at past sales and reviews total world Cancer Immunotherapy Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Cancer Immunotherapy Drugs sales for 2023 through 2029. With Cancer Immunotherapy Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cancer Immunotherapy Drugs industry.
This Insight Report provides a comprehensive analysis of the global Cancer Immunotherapy Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Cancer Immunotherapy Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Cancer Immunotherapy Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cancer Immunotherapy Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cancer Immunotherapy Drugs.
United States market for Cancer Immunotherapy Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Cancer Immunotherapy Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Cancer Immunotherapy Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Cancer Immunotherapy Drugs players cover AbbVie, Johnson & Johnson, Novartis, Gilead Sciences, Roche, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Cancer Immunotherapy Drugs market by product type, application, key players and key regions and countries.
Segmentation by Type:
滨尘尘耻苍别听颁丑别肠办辫辞颈苍迟听滨苍丑颈产颈迟辞谤蝉
颁测迟辞办颈苍别-叠补蝉别诲听滨尘尘耻苍辞迟丑别谤补辫测
颁础搁-罢听颁别濒濒听罢丑别谤补辫测
Other
Segmentation by Application:
Lung Cancer
Breast Cancer
Prostate Cancer
Blood-related Cancer
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Segmentation by Type:
滨尘尘耻苍别听颁丑别肠办辫辞颈苍迟听滨苍丑颈产颈迟辞谤蝉
颁测迟辞办颈苍别-叠补蝉别诲听滨尘尘耻苍辞迟丑别谤补辫测
颁础搁-罢听颁别濒濒听罢丑别谤补辫测
Other
Segmentation by Application:
Lung Cancer
Breast Cancer
Prostate Cancer
Blood-related Cancer
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AbbVie
Johnson & Johnson
Novartis
Gilead Sciences
Roche
Bristol-Myers Squibb
Amgen
AstraZeneca
Merck & Co
Takeda
Merck KGaA
Seagen
Eli Lilly
Ono Pharmaceutical
Pfizer
GSK
Exelixis
Regeneron
Innovent
Hengrui Medicine

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Cancer Immunotherapy Drugs 麻豆原创 Size 2019-2030
2.1.2 Cancer Immunotherapy Drugs 麻豆原创 Size CAGR by Region (2019 VS 2023 VS 2030)
2.1.3 World Current & Future Analysis for Cancer Immunotherapy Drugs by Country/Region, 2019, 2023 & 2030
2.2 Cancer Immunotherapy Drugs Segment by Type
2.2.1 滨尘尘耻苍别听颁丑别肠办辫辞颈苍迟听滨苍丑颈产颈迟辞谤蝉
2.2.2 颁测迟辞办颈苍别-叠补蝉别诲听滨尘尘耻苍辞迟丑别谤补辫测
2.2.3 颁础搁-罢听颁别濒濒听罢丑别谤补辫测
2.2.4 Other
2.3 Cancer Immunotherapy Drugs 麻豆原创 Size by Type
2.3.1 Cancer Immunotherapy Drugs 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Cancer Immunotherapy Drugs 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 Cancer Immunotherapy Drugs Segment by Application
2.4.1 Lung Cancer
2.4.2 Breast Cancer
2.4.3 Prostate Cancer
2.4.4 Blood-related Cancer
2.4.5 Other
2.5 Cancer Immunotherapy Drugs 麻豆原创 Size by Application
2.5.1 Cancer Immunotherapy Drugs 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Cancer Immunotherapy Drugs 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 Cancer Immunotherapy Drugs 麻豆原创 Size by Player
3.1 Cancer Immunotherapy Drugs 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Cancer Immunotherapy Drugs Revenue by Player (2019-2024)
3.1.2 Global Cancer Immunotherapy Drugs Revenue 麻豆原创 Share by Player (2019-2024)
3.2 Global Cancer Immunotherapy Drugs Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Cancer Immunotherapy Drugs by Region
4.1 Cancer Immunotherapy Drugs 麻豆原创 Size by Region (2019-2024)
4.2 Global Cancer Immunotherapy Drugs Annual Revenue by Country/Region (2019-2024)
4.3 Americas Cancer Immunotherapy Drugs 麻豆原创 Size Growth (2019-2024)
4.4 APAC Cancer Immunotherapy Drugs 麻豆原创 Size Growth (2019-2024)
4.5 Europe Cancer Immunotherapy Drugs 麻豆原创 Size Growth (2019-2024)
4.6 Middle East & Africa Cancer Immunotherapy Drugs 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas Cancer Immunotherapy Drugs 麻豆原创 Size by Country (2019-2024)
5.2 Americas Cancer Immunotherapy Drugs 麻豆原创 Size by Type (2019-2024)
5.3 Americas Cancer Immunotherapy Drugs 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Cancer Immunotherapy Drugs 麻豆原创 Size by Region (2019-2024)
6.2 APAC Cancer Immunotherapy Drugs 麻豆原创 Size by Type (2019-2024)
6.3 APAC Cancer Immunotherapy Drugs 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Cancer Immunotherapy Drugs 麻豆原创 Size by Country (2019-2024)
7.2 Europe Cancer Immunotherapy Drugs 麻豆原创 Size by Type (2019-2024)
7.3 Europe Cancer Immunotherapy Drugs 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Cancer Immunotherapy Drugs by Region (2019-2024)
8.2 Middle East & Africa Cancer Immunotherapy Drugs 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa Cancer Immunotherapy Drugs 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Cancer Immunotherapy Drugs 麻豆原创 Forecast
10.1 Global Cancer Immunotherapy Drugs Forecast by Region (2025-2030)
10.1.1 Global Cancer Immunotherapy Drugs Forecast by Region (2025-2030)
10.1.2 Americas Cancer Immunotherapy Drugs Forecast
10.1.3 APAC Cancer Immunotherapy Drugs Forecast
10.1.4 Europe Cancer Immunotherapy Drugs Forecast
10.1.5 Middle East & Africa Cancer Immunotherapy Drugs Forecast
10.2 Americas Cancer Immunotherapy Drugs Forecast by Country (2025-2030)
10.2.1 United States 麻豆原创 Cancer Immunotherapy Drugs Forecast
10.2.2 Canada 麻豆原创 Cancer Immunotherapy Drugs Forecast
10.2.3 Mexico 麻豆原创 Cancer Immunotherapy Drugs Forecast
10.2.4 Brazil 麻豆原创 Cancer Immunotherapy Drugs Forecast
10.3 APAC Cancer Immunotherapy Drugs Forecast by Region (2025-2030)
10.3.1 China Cancer Immunotherapy Drugs 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Cancer Immunotherapy Drugs Forecast
10.3.3 Korea 麻豆原创 Cancer Immunotherapy Drugs Forecast
10.3.4 Southeast Asia 麻豆原创 Cancer Immunotherapy Drugs Forecast
10.3.5 India 麻豆原创 Cancer Immunotherapy Drugs Forecast
10.3.6 Australia 麻豆原创 Cancer Immunotherapy Drugs Forecast
10.4 Europe Cancer Immunotherapy Drugs Forecast by Country (2025-2030)
10.4.1 Germany 麻豆原创 Cancer Immunotherapy Drugs Forecast
10.4.2 France 麻豆原创 Cancer Immunotherapy Drugs Forecast
10.4.3 UK 麻豆原创 Cancer Immunotherapy Drugs Forecast
10.4.4 Italy 麻豆原创 Cancer Immunotherapy Drugs Forecast
10.4.5 Russia 麻豆原创 Cancer Immunotherapy Drugs Forecast
10.5 Middle East & Africa Cancer Immunotherapy Drugs Forecast by Region (2025-2030)
10.5.1 Egypt 麻豆原创 Cancer Immunotherapy Drugs Forecast
10.5.2 South Africa 麻豆原创 Cancer Immunotherapy Drugs Forecast
10.5.3 Israel 麻豆原创 Cancer Immunotherapy Drugs Forecast
10.5.4 Turkey 麻豆原创 Cancer Immunotherapy Drugs Forecast
10.6 Global Cancer Immunotherapy Drugs Forecast by Type (2025-2030)
10.7 Global Cancer Immunotherapy Drugs Forecast by Application (2025-2030)
10.7.1 GCC Countries 麻豆原创 Cancer Immunotherapy Drugs Forecast
11 Key Players Analysis
11.1 AbbVie
11.1.1 AbbVie Company Information
11.1.2 AbbVie Cancer Immunotherapy Drugs Product Offered
11.1.3 AbbVie Cancer Immunotherapy Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 AbbVie Main Business Overview
11.1.5 AbbVie Latest Developments
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Information
11.2.2 Johnson & Johnson Cancer Immunotherapy Drugs Product Offered
11.2.3 Johnson & Johnson Cancer Immunotherapy Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 Johnson & Johnson Main Business Overview
11.2.5 Johnson & Johnson Latest Developments
11.3 Novartis
11.3.1 Novartis Company Information
11.3.2 Novartis Cancer Immunotherapy Drugs Product Offered
11.3.3 Novartis Cancer Immunotherapy Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Novartis Main Business Overview
11.3.5 Novartis Latest Developments
11.4 Gilead Sciences
11.4.1 Gilead Sciences Company Information
11.4.2 Gilead Sciences Cancer Immunotherapy Drugs Product Offered
11.4.3 Gilead Sciences Cancer Immunotherapy Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 Gilead Sciences Main Business Overview
11.4.5 Gilead Sciences Latest Developments
11.5 Roche
11.5.1 Roche Company Information
11.5.2 Roche Cancer Immunotherapy Drugs Product Offered
11.5.3 Roche Cancer Immunotherapy Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 Roche Main Business Overview
11.5.5 Roche Latest Developments
11.6 Bristol-Myers Squibb
11.6.1 Bristol-Myers Squibb Company Information
11.6.2 Bristol-Myers Squibb Cancer Immunotherapy Drugs Product Offered
11.6.3 Bristol-Myers Squibb Cancer Immunotherapy Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 Bristol-Myers Squibb Main Business Overview
11.6.5 Bristol-Myers Squibb Latest Developments
11.7 Amgen
11.7.1 Amgen Company Information
11.7.2 Amgen Cancer Immunotherapy Drugs Product Offered
11.7.3 Amgen Cancer Immunotherapy Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 Amgen Main Business Overview
11.7.5 Amgen Latest Developments
11.8 AstraZeneca
11.8.1 AstraZeneca Company Information
11.8.2 AstraZeneca Cancer Immunotherapy Drugs Product Offered
11.8.3 AstraZeneca Cancer Immunotherapy Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 AstraZeneca Main Business Overview
11.8.5 AstraZeneca Latest Developments
11.9 Merck & Co
11.9.1 Merck & Co Company Information
11.9.2 Merck & Co Cancer Immunotherapy Drugs Product Offered
11.9.3 Merck & Co Cancer Immunotherapy Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.9.4 Merck & Co Main Business Overview
11.9.5 Merck & Co Latest Developments
11.10 Takeda
11.10.1 Takeda Company Information
11.10.2 Takeda Cancer Immunotherapy Drugs Product Offered
11.10.3 Takeda Cancer Immunotherapy Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.10.4 Takeda Main Business Overview
11.10.5 Takeda Latest Developments
11.11 Merck KGaA
11.11.1 Merck KGaA Company Information
11.11.2 Merck KGaA Cancer Immunotherapy Drugs Product Offered
11.11.3 Merck KGaA Cancer Immunotherapy Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.11.4 Merck KGaA Main Business Overview
11.11.5 Merck KGaA Latest Developments
11.12 Seagen
11.12.1 Seagen Company Information
11.12.2 Seagen Cancer Immunotherapy Drugs Product Offered
11.12.3 Seagen Cancer Immunotherapy Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.12.4 Seagen Main Business Overview
11.12.5 Seagen Latest Developments
11.13 Eli Lilly
11.13.1 Eli Lilly Company Information
11.13.2 Eli Lilly Cancer Immunotherapy Drugs Product Offered
11.13.3 Eli Lilly Cancer Immunotherapy Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.13.4 Eli Lilly Main Business Overview
11.13.5 Eli Lilly Latest Developments
11.14 Ono Pharmaceutical
11.14.1 Ono Pharmaceutical Company Information
11.14.2 Ono Pharmaceutical Cancer Immunotherapy Drugs Product Offered
11.14.3 Ono Pharmaceutical Cancer Immunotherapy Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.14.4 Ono Pharmaceutical Main Business Overview
11.14.5 Ono Pharmaceutical Latest Developments
11.15 Pfizer
11.15.1 Pfizer Company Information
11.15.2 Pfizer Cancer Immunotherapy Drugs Product Offered
11.15.3 Pfizer Cancer Immunotherapy Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.15.4 Pfizer Main Business Overview
11.15.5 Pfizer Latest Developments
11.16 GSK
11.16.1 GSK Company Information
11.16.2 GSK Cancer Immunotherapy Drugs Product Offered
11.16.3 GSK Cancer Immunotherapy Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.16.4 GSK Main Business Overview
11.16.5 GSK Latest Developments
11.17 Exelixis
11.17.1 Exelixis Company Information
11.17.2 Exelixis Cancer Immunotherapy Drugs Product Offered
11.17.3 Exelixis Cancer Immunotherapy Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.17.4 Exelixis Main Business Overview
11.17.5 Exelixis Latest Developments
11.18 Regeneron
11.18.1 Regeneron Company Information
11.18.2 Regeneron Cancer Immunotherapy Drugs Product Offered
11.18.3 Regeneron Cancer Immunotherapy Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.18.4 Regeneron Main Business Overview
11.18.5 Regeneron Latest Developments
11.19 Innovent
11.19.1 Innovent Company Information
11.19.2 Innovent Cancer Immunotherapy Drugs Product Offered
11.19.3 Innovent Cancer Immunotherapy Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.19.4 Innovent Main Business Overview
11.19.5 Innovent Latest Developments
11.20 Hengrui Medicine
11.20.1 Hengrui Medicine Company Information
11.20.2 Hengrui Medicine Cancer Immunotherapy Drugs Product Offered
11.20.3 Hengrui Medicine Cancer Immunotherapy Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.20.4 Hengrui Medicine Main Business Overview
11.20.5 Hengrui Medicine Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.